Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers
Drug Metabolism and Pharmacokinetics · 2020-12 · 35 (6) · 539-547
DOI: 10.1016/j.dmpk.2020.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2020-12. Verfasst von Keito Amai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The aldo-keto reductase (AKR) and short-chain dehydrogenase/reductase (SDR) superfamilies are responsible for the reduction in compounds containing the aldehyde, ketone, and quinone groups. In humans, 12 AKR isoforms (AKR1A1, AKR1B1, AKR1B10, AKR1B15, AKR1C1, AKR1C2, AKR1C3, AKR1C4, AKR1D1, AKR1E2, AKR7A2, and AKR7A3) and 6 SDR isoforms (CBR1, CBR3, CBR4, HSD11B1, DHRS4, and DCXR) have been found to catalyze the reduction in xenobiotics, but their hepatic expression levels are unclear. The purpose of this study is to determine the absolute mRNA expression levels of these 18 isoforms in the human liver. In 22 human livers, all isoforms, except for AKR1B15, are expressed, and AKR1C2 (on average 1.6 × 106 copy/μg total RNA), AKR1C3 (1.3 × 106), AKR1C1 (1.3 × 106), CBR1 (9.7 × 105), and HSD11B1 (1.1 × 106) are abundant, representing 67% of the total expression of reductases in the liver. The expression levels of AKR1C2, AKR1C3, AKR1C1, CBR1, and HSD11B1 are significantly correlated with each other, except between AKR1C2 and CBR1, suggesting that they might be regulated by common factor(s). In conclusion, this study comprehensively determined the absolute expression of mRNA expression of each AKR and SDR isoform in the human liver.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazaw…
- Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Amai, K., Fukami, T., Ichida, H., Watanabe, A., Nakano, M., Watanabe, K., & Nakajima, M. (2020). Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers. Drug Metabolism and Pharmacokinetics, 35(6), 539-547. https://doi.org/10.1016/j.dmpk.2020.08.004
Vancouver
Amai K, Fukami T, Ichida H, Watanabe A, Nakano M, Watanabe K, et al. Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers. Drug Metabolism and Pharmacokinetics. 2020;35(6):539-547. doi:10.1016/j.dmpk.2020.08.004
BibTeX
@article{Amai2020,
author = {Amai, Keito and Fukami, Tatsuki and Ichida, Hiroyuki and Watanabe, Akiko and Nakano, Masataka and Watanabe, Kengo and Nakajima, Miki},
title = {Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2020},
volume = {35},
number = {6},
pages = {539--547},
doi = {10.1016/j.dmpk.2020.08.004}
}
EUVIMED